Published Sep 22, 2026
Theriva Biologics (TOVX): Oncolytic Virus Option Against a Going Concern
In-depth research on TOVX covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,544 words16 min read
Read report